journal article·2026-02

Dual Metabolic Rewiring Amplifies Cellular Oxidation and Reverses Immunosuppression for Combating Orthotopic Triple‐Negative Breast Cancer

Qiu‐Yi Duan, Shi‐Hao Wang, Ke‐Fei Xu, Yuxin Guo, Xiaoyang Liu, Shao‐Zhe Wang, Bai‐Hui Shan, Hui‐Heng Feng, Qiming Xu, Yang Shen, Fu‐Gen Wu

Advanced Functional Materials· Volume 36· Issue 13
Publisher page

Abstract

Abstract Abnormal glucose/lactate metabolism is one of the key hallmarks of a tumor. Leveraging the excessive metabolite lactate to generate reactive oxygen species (ROS) by lactate oxidase (LOx) has become an efficient method for cancer therapy. However, the hypoxic tumor microenvironment (TME) and ROS‐scavenging enzymes largely restrict the catalytic activity of LOx. Herein, we design an ROS generator composed of LOx‐encapsulated and 7‐ethyl‐10‐hydroxycamptothecin (SN‐38)‐ and tamoxifen (TAM)‐coloaded membrane fusion liposomes, which can directly release cargoes via fusion with cancer cell membranes. Through the glycolysis promotion and mitochondrial respiration inhibition by TAM, and the antioxidant enzyme downregulation by SN‐38, the generator not only spares oxygen and increases intracellular lactate for LOx catalysis to yield cytotoxic H 2 O 2 , but also avoids ROS removal, realizing triple‐amplified ROS production and effective cancer cell killing. In the TME of an orthotopic breast cancer model, the generator consumes lactate and produces immunostimulatory H 2 O 2 , thereby promoting the M1‐like polarization of tumor‐associated macrophages and suppressing regulatory T cells to remodel the immunosuppressive TME. Additionally, the generator inhibits angiogenesis and further cancer metastasis via hypoxia inducible factor‐1α (HIF‐1α) signaling blockage. Collectively, this work provides an inspirational example of using a glucose/lactate metabolism interference strategy to fight against orthotopic triple‐negative breast cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer, Hypoxia, and Metabolism · Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Digital Medical Engineering Jiangsu Key Laboratory for Biomaterials and Devices School of Biological Science and Medical Engineering Southeast University 2 Southeast University Road Nanjing 211189 P. R. China

Department of Orthopedic Oncology Beijing Jishuitan Hospital Capital Medical University Beijing 100031 P. R. China

Department of Obstetrics and Gynecology Zhongda Hospital School of Medicine Southeast University Nanjing 210009 P. R. China

Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine Nanjing 210009 P. R. China

Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor Nanning 530021 P. R. China

Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University) Ministry of Education Nanning 530021 P. R. China

Funding

National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1158/2159-8290.CD-12-034510.1158/2159-8290.CD-12-0345 ↗
2. 10.1002/smll.20230779410.1002/smll.202307794 ↗
3. 10.1016/j.critrevonc.2017.04.00510.1016/j.critrevonc.2017.04.005 ↗
4. 10.1038/nrc.2016.7710.1038/nrc.2016.77 ↗
5. 10.1038/nrc303810.1038/nrc3038 ↗
6. 10.1085/jgp.8.6.51910.1085/jgp.8.6.519 ↗
7. 10.1016/j.canlet.2024.21683710.1016/j.canlet.2024.216837 ↗
8. 10.3389/fonc.2020.0023110.3389/fonc.2020.00231 ↗
9. 10.3390/antib1003002510.3390/antib10030025 ↗
10. 10.1016/j.apsb.2015.05.00710.1016/j.apsb.2015.05.007 ↗
11. 10.1002/mog2.8710.1002/mog2.87 ↗
12. 10.1016/j.jcis.2025.13797910.1016/j.jcis.2025.137979 ↗
13. 10.1038/nature1349010.1038/nature13490 ↗
14. 10.1038/s41467-022-32521-810.1038/s41467-022-32521-8 ↗
15. 10.1038/s41590-024-01999-310.1038/s41590-024-01999-3 ↗
16. 10.3389/fonc.2023.117553210.3389/fonc.2023.1175532 ↗
17. 10.3390/ijms22241334610.3390/ijms222413346 ↗
18. 10.1016/j.tibs.2018.10.01110.1016/j.tibs.2018.10.011 ↗
19. 10.1016/j.engmed.2024.10002710.1016/j.engmed.2024.100027 ↗
20. 10.1002/adma.20230551210.1002/adma.202305512 ↗
21. 10.1016/j.cmet.2016.08.01110.1016/j.cmet.2016.08.011 ↗
22. 10.1038/s41586-020-03045-210.1038/s41586-020-03045-2 ↗
23. 10.1002/adfm.20230272810.1002/adfm.202302728 ↗
24. 10.1002/advs.20230068610.1002/advs.202300686 ↗
25. 10.1038/s41467-021-25561-z10.1038/s41467-021-25561-z ↗
26. 10.1126/scitranslmed.add271210.1126/scitranslmed.add2712 ↗
27. 10.1002/advs.20210259510.1002/advs.202102595 ↗
28. 10.1002/adma.20190463910.1002/adma.201904639 ↗
29. 10.1002/advs.20220480810.1002/advs.202204808 ↗
30. 10.1021/acsami.2c0725410.1021/acsami.2c07254 ↗
31. 10.1002/anie.20200146910.1002/anie.202001469 ↗
32. 10.1002/anie.20240563910.1002/anie.202405639 ↗
33. 10.1021/acsami.2c1896010.1021/acsami.2c18960 ↗
34. 10.1016/j.biomaterials.2025.12320310.1016/j.biomaterials.2025.123203 ↗
35. 10.1007/s12274-022-5301-710.1007/s12274-022-5301-7 ↗
36. 10.1002/adfm.20242082510.1002/adfm.202420825 ↗
37. 10.1002/adma.20220795110.1002/adma.202207951 ↗
38. 10.3390/ijms23241589310.3390/ijms232415893 ↗
39. 10.1016/j.jcis.2025.13782910.1016/j.jcis.2025.137829 ↗
40. 10.3390/cells901008710.3390/cells9010087 ↗
41. 10.1021/acs.nanolett.9b0033610.1021/acs.nanolett.9b00336 ↗
42. 10.1016/j.jconrel.2023.03.03810.1016/j.jconrel.2023.03.038 ↗
43. 10.1152/physiol.00016.201710.1152/physiol.00016.2017 ↗
44. 10.7150/ijbs.2005210.7150/ijbs.20052 ↗
45. 10.1002/adfm.20210647110.1002/adfm.202106471 ↗
46. Xu G. · Mol. Med. Rep. · 2018 · 17 · 6621
47. 10.1039/D3MD00632H10.1039/D3MD00632H ↗
48. 10.1158/0008-5472.CAN-15-219710.1158/0008-5472.CAN-15-2197 ↗
49. 10.1002/anie.20201441510.1002/anie.202014415 ↗
50. 10.1007/s00262-023-03382-x10.1007/s00262-023-03382-x ↗
51. 10.1002/mog2.8910.1002/mog2.89 ↗
52. 10.1007/s00432-004-0642-z10.1007/s00432-004-0642-z ↗